Literature DB >> 35713693

Comprehensive analysis of novel prognosis-related proteomic signature effectively improve risk stratification and precision treatment for patients with cervical cancer.

Xiaoyu Ji1, Guangdi Chu2, Yulong Chen1, Jinwen Jiao1, Teng Lv1, Qin Yao3.   

Abstract

OBJECTIVE: Cervical cancer (CC) is one of the most common types of malignant female cancer, and its incidence and mortality are not optimistic. Protein panels can be a powerful prognostic factor for many types of cancer. The purpose of our study was to investigate a proteomic panel to predict the survival of patients with common CC. METHODS AND
RESULTS: The protein expression and clinicopathological data of CC were downloaded from The Cancer Proteome Atlas and The Cancer Genome Atlas database, respectively. We selected the prognosis-related proteins (PRPs) by univariate Cox regression analysis and found that the results of functional enrichment analysis were mainly related to apoptosis. We used Kaplan-Meier analysis and multivariable Cox regression analysis further to screen PRPs to establish a prognostic model, including BCL2, SMAD3, and 4EBP1-pT70. The signature was verified to be independent predictors of OS by Cox regression analysis and the area under curves. Nomogram and subgroup classification were established based on the signature to verify its clinical application. Furthermore, we looked for the co-expressed proteins of three-protein panel as potential prognostic proteins.
CONCLUSION: A proteomic signature independently predicted OS of CC patients, and the predictive ability was better than the clinicopathological characteristics. This signature can help improve prediction for clinical outcome and provides new targets for CC treatment.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cervical cancer; Prognosis; Proteomic panel; TCGA; TCPA

Year:  2022        PMID: 35713693     DOI: 10.1007/s00404-022-06642-w

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  46 in total

1.  Cancer of the cervix uteri.

Authors:  Neerja Bhatla; Daisuke Aoki; Daya Nand Sharma; Rengaswamy Sankaranarayanan
Journal:  Int J Gynaecol Obstet       Date:  2018-10       Impact factor: 3.561

2.  Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer.

Authors:  Chel Hun Choi; Joon-Yong Chung; Jun Hyeok Kang; E Sun Paik; Yoo-Young Lee; Won Park; Sun-Ju Byeon; Eun Joo Chung; Byoung-Gie Kim; Stephen M Hewitt; Duk-Soo Bae
Journal:  Gynecol Oncol       Date:  2020-02-24       Impact factor: 5.482

3.  A 10-gene prognostic methylation signature for stage I-III cervical cancer.

Authors:  Shengyun Cai; Xiaomin Yu; Zhongyi Gu; Qingqing Yang; Biwei Wen; Jizi Sheng; Rui Guan
Journal:  Arch Gynecol Obstet       Date:  2020-04-09       Impact factor: 2.344

4.  Utility of Reverse-Phase Protein Array for Refining Precision Oncology.

Authors:  Mari Masuda; Tesshi Yamada
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

5.  A 15-long non-coding RNA signature to improve prognosis prediction of cervical squamous cell carcinoma.

Authors:  Xiaogang Mao; Xiaomin Qin; Lin Li; Jinting Zhou; Min Zhou; Xianxian Li; Ying Xu; Liyun Yuan; Qiong-Na Liu; Hui Xing
Journal:  Gynecol Oncol       Date:  2018-03-08       Impact factor: 5.482

6.  Comparison of adenocarcinoma (ACA) and squamous cell carcinoma (SCC) of the uterine cervix in a sub-optimally screened cohort: a population-based epidemiologic study of 51,842 women in Brazil.

Authors:  Angélica Nogueira-Rodrigues; Carlos Gil Ferreira; Anke Bergmann; Suzana Sales de Aguiar; Luiz Claudio Santos Thuler
Journal:  Gynecol Oncol       Date:  2014-08-14       Impact factor: 5.482

Review 7.  Cervical cancer: Biomarkers for diagnosis and treatment.

Authors:  Subramanyam Dasari; Rajendra Wudayagiri; Lokanatha Valluru
Journal:  Clin Chim Acta       Date:  2015-03-12       Impact factor: 3.786

8.  A microRNA expression signature for cervical cancer prognosis.

Authors:  Xiaoxia Hu; Julie K Schwarz; James S Lewis; Phyllis C Huettner; Janet S Rader; Joseph O Deasy; Perry W Grigsby; Xiaowei Wang
Journal:  Cancer Res       Date:  2010-02-02       Impact factor: 12.701

9.  Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients.

Authors:  Sou Hirose; Naoya Murakami; Kazuaki Takahashi; Ikumi Kuno; Daisuke Takayanagi; Yuka Asami; Maiko Matsuda; Yoko Shimada; Shotaro Yamano; Kuniko Sunami; Kazushi Yoshida; Takayuki Honda; Tomomi Nakahara; Tomoko Watanabe; Masaaki Komatsu; Ryuji Hamamoto; Mayumi Kobayashi Kato; Koji Matsumoto; Kae Okuma; Takafumi Kuroda; Aikou Okamoto; Jun Itami; Takashi Kohno; Tomoyasu Kato; Kouya Shiraishi; Hiroshi Yoshida
Journal:  Gynecol Oncol       Date:  2019-11-19       Impact factor: 5.482

10.  Proteomic profiling reveals a signature for optimizing prognostic prediction in Colon Cancer.

Authors:  Zezhi Shan; Dakui Luo; Qi Liu; Sanjun Cai; Renjie Wang; Yanlei Ma; Xinxiang Li
Journal:  J Cancer       Date:  2021-02-22       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.